madman
Super Moderator
36:01 Long-term TRT and receptor sensitivity concerns
42:30 Androgen receptors and long-term adaptation
KYZATREX: UNIQUE LYMPHATIC ABSORPTION
Testosterone isn’t just about libido. It’s one of the most important metabolic signals in the body, yet most people never test it, and most systems don’t treat it correctly.
In this episode, we break down why testosterone is more than a “male hormone” and how it connects to metabolism, mitochondria, cognition, and long-term health. We get into why levels are dropping in younger populations, why traditional diagnostics miss the real problem, and why free testosterone matters more than total testosterone.
We also explore how next-gen TRT approaches aim to align with natural circadian rhythms instead of overriding biology, what that means for energy, fertility, and long-term outcomes, and why most people are still looking at the wrong markers.
This isn’t about chasing higher numbers It’s about restoring function and understanding the system.
Timestamps:
00:00 What testosterone actually does beyond libido
00:27 Why testosterone is a critical health biomarker
01:03 Decline in young men and what’s driving it
01:31 Oral TRT vs injections explained
02:03 Why most people misunderstand testosterone
02:25 Background of TRT and pharma limitations
03:25 Myths around cardiovascular and prostate risk
05:10 Testosterone as a full-body metabolic signal
05:38 Why testing is broken in modern medicine
06:19 Why testosterone should be a standard biomarker
07:58 Lack of access and issues for women
10:18 Circadian rhythm and natural hormone patterns
12:21 Free testosterone vs total testosterone
14:09 Hematocrit risks and TRT safety differences
15:07 Fertility, LH, FSH and long-term impact
17:24 Real-world TRT experience and outcomes
20:17 Why total testosterone can mislead you
22:27 What to actually test in bloodwork
25:11 Lifestyle, stress, and environmental impac
t29:10 Why testosterone is dropping in younger men
30:52 When you should start testing testosterone
32:36 Stress, overtraining, and hormonal collapse
34:12 Longevity basics: strength, VO2 max, body composition
36:01 Long-term TRT and receptor sensitivity concerns
38:19 Testosterone and mitochondrial function
40:13 Cellular health, disease risk, and hormones
42:30 Androgen receptors and long-term adaptation
46:16 Why there’s no TRT for women yet
48:05 Future of hormone therapy for women
51:16 Where to learn more and next steps
* Generally, cFT correlates well with mFT but various proposed algorithms for calculation of FT perform unequally, giving rise to disparate results for cFT. For example, for the most-commonly used Vermeulen formula, notwithstanding an excellent correlation, a positive bias of around 20% is observed between FT measured by ED LC-MS/MS and calculations (1).
* The established reference ranges are in line with previous reports of mFT (22,33,34) and may potentially be used as a reference data set for other methods. However, before these data can be more broadly implemented in clinical laboratories and clinical care, harmonization/standardization and cross-validation of existing mFT methods are required. Harmonization/standardization initiatives are crucial to move forward, given the increasing interest in mFT. Indeed, more clinical and commercial laboratories have been developing in-house mFT methods with improved throughput and shorter dialysis times (23,35,36). However, without the existence of a reference measurement system and reference measurement procedures, the performance of existing routine methods in terms of calibration and sample related effects cannot be assessed, nor can the calibration of the assays be traceable to a common reference point. This may result in large differences between methods.
42:30 Androgen receptors and long-term adaptation
KYZATREX: UNIQUE LYMPHATIC ABSORPTION
Testosterone isn’t just about libido. It’s one of the most important metabolic signals in the body, yet most people never test it, and most systems don’t treat it correctly.
In this episode, we break down why testosterone is more than a “male hormone” and how it connects to metabolism, mitochondria, cognition, and long-term health. We get into why levels are dropping in younger populations, why traditional diagnostics miss the real problem, and why free testosterone matters more than total testosterone.
We also explore how next-gen TRT approaches aim to align with natural circadian rhythms instead of overriding biology, what that means for energy, fertility, and long-term outcomes, and why most people are still looking at the wrong markers.
This isn’t about chasing higher numbers It’s about restoring function and understanding the system.
Timestamps:
00:00 What testosterone actually does beyond libido
00:27 Why testosterone is a critical health biomarker
01:03 Decline in young men and what’s driving it
01:31 Oral TRT vs injections explained
02:03 Why most people misunderstand testosterone
02:25 Background of TRT and pharma limitations
03:25 Myths around cardiovascular and prostate risk
05:10 Testosterone as a full-body metabolic signal
05:38 Why testing is broken in modern medicine
06:19 Why testosterone should be a standard biomarker
07:58 Lack of access and issues for women
10:18 Circadian rhythm and natural hormone patterns
12:21 Free testosterone vs total testosterone
14:09 Hematocrit risks and TRT safety differences
15:07 Fertility, LH, FSH and long-term impact
17:24 Real-world TRT experience and outcomes
20:17 Why total testosterone can mislead you
22:27 What to actually test in bloodwork
25:11 Lifestyle, stress, and environmental impac
t29:10 Why testosterone is dropping in younger men
30:52 When you should start testing testosterone
32:36 Stress, overtraining, and hormonal collapse
34:12 Longevity basics: strength, VO2 max, body composition
36:01 Long-term TRT and receptor sensitivity concerns
38:19 Testosterone and mitochondrial function
40:13 Cellular health, disease risk, and hormones
42:30 Androgen receptors and long-term adaptation
46:16 Why there’s no TRT for women yet
48:05 Future of hormone therapy for women
51:16 Where to learn more and next steps
* Generally, cFT correlates well with mFT but various proposed algorithms for calculation of FT perform unequally, giving rise to disparate results for cFT. For example, for the most-commonly used Vermeulen formula, notwithstanding an excellent correlation, a positive bias of around 20% is observed between FT measured by ED LC-MS/MS and calculations (1).
* The established reference ranges are in line with previous reports of mFT (22,33,34) and may potentially be used as a reference data set for other methods. However, before these data can be more broadly implemented in clinical laboratories and clinical care, harmonization/standardization and cross-validation of existing mFT methods are required. Harmonization/standardization initiatives are crucial to move forward, given the increasing interest in mFT. Indeed, more clinical and commercial laboratories have been developing in-house mFT methods with improved throughput and shorter dialysis times (23,35,36). However, without the existence of a reference measurement system and reference measurement procedures, the performance of existing routine methods in terms of calibration and sample related effects cannot be assessed, nor can the calibration of the assays be traceable to a common reference point. This may result in large differences between methods.
